Drug startups coalesce around condensates

Three startups debuted in late 2020, all aiming to treat disease by manipulating the physiochemical and regulatory processes in cells that drive membraneless hubs associated with disease pathogenesis. The field’s frontrunner, Dewpoint Therapeutics, also signed a major research pact last month with Pfizer — Dewpoint’s third such deal with a large pharma partner since the company’s inception two years ago…